A read on what the numbers say about Q1 and Q2 2026, set against 2024 and 2025. New-patient demand and operational quality are up sharply. Topline production has softened. This is where the two stories meet.
Troy is operationally healthier than a year ago: case acceptance climbed from 64% to 80%, no-shows fell from 7.4% to 1.0%, and the team has worked roughly $685,458 out of the unscheduled-treatment backlog. Demand is up hard, with qualified phone leads up 222% year over year.
The one number going the wrong way is the one that matters most: production is down 7.7% year to date ($4,362,095 to $4,026,577 for Jan–May), with Q1 off 10.0%. The funnel is full and the team is converting the chair well. The gap is throughput: turning a surge of calls and leads into booked, completed, higher-value production.
Monthly gross production has held a wide band of roughly $650K to $980K for two years, but the trend since mid-2025 is down. Full-year 2025 finished at $9,828,133, 3.2% below 2024. Jan–May 2026 sits 7.7% behind the same period last year, dragged most by a soft May ($652,891).
The waterfalls below bridge last year's production to this year's, month by month. April 2026 actually beat April 2025; the YTD gap is concentrated in January and May.
| Quarter | 2024 | 2025 | 2026 | YoY ’25 | YoY ’26 |
|---|---|---|---|---|---|
| Q1 | $2,463,835 | $2,729,729 | $2,456,521 | +10.8% | -10.0% |
| Q2 | $2,788,036 | $2,466,428 | – | -11.5% | – |
| Q3 | $2,419,845 | $2,209,971 | – | -8.7% | – |
| Q4 | $2,478,942 | $2,422,004 | – | -2.3% | – |
| FY | $10,150,659 | $9,828,133 | – | -3.2% | – |
New patients are not the problem. Troy added 446.0 new patients in the first five months of 2026, essentially flat to the 457.0 it added in the same window of 2025 and ahead of 2024. The acquisition engine is delivering people through the door. The question is what happens after they arrive.
Case acceptance has stepped up materially in 2026, holding in the high-70s to high-80s after running in the low-60s through 2025. At the same time, the unscheduled-treatment opportunity has fallen from $4,656,963 to $3,971,505, meaning diagnosed work that used to sit unscheduled is getting booked. Both point the same direction: better chairside conversion.
No-shows and cancellations are the quiet killers of a dental schedule, and both have improved. No-show rate has fallen to near zero in 2026 from the 7% to 10% range it ran in 2024. That is real recovered chair time and a sign the front office and reminder workflow are working.
Phone demand has stepped up dramatically in 2026. Total tracked calls for Jan–May jumped from 479 to 1,461 (+205%), and qualified calls from 222 to 714 (+222%). On the implant side, the CRM took in 2,220 leads in 2025 and is on a similar pace in 2026. The leads are there. The drop-off is in the middle of the funnel.
Across all of 2025, the implant pipeline turned 2,220 leads into 280 booked consults, 179 consults held, and 41 closed cases worth $883,737. That is roughly 13% of leads booking, and under 2% of leads becoming cases. The biggest losses happen before the consult: most leads never book. Speed-to-lead and booking conversion are the highest-leverage fixes.
| Month | Production | New Pts | Accept | No-show | Unsched $ | Calls | Impl Leads | Impl Sales |
|---|---|---|---|---|---|---|---|---|
| 2025-01 | $856,191 | 88 | 69% | 8% | $4,337,646 | 100 | 179 | 8 |
| 2025-02 | $976,313 | 93 | 63% | 8% | $4,329,481 | 108 | 189 | 6 |
| 2025-03 | $897,225 | 95 | 65% | 8% | $4,383,598 | 85 | 218 | 5 |
| 2025-04 | $852,277 | 102 | 60% | 5% | $4,460,417 | 112 | 198 | 1 |
| 2025-05 | $780,089 | 79 | 61% | 8% | $4,492,166 | 74 | 226 | 1 |
| 2025-06 | $834,063 | 87 | 62% | 7% | $4,449,012 | 77 | 163 | 2 |
| 2025-07 | $910,058 | 87 | 64% | 5% | $4,408,822 | 121 | 130 | 7 |
| 2025-08 | $695,720 | 97 | 61% | 6% | $4,431,402 | 139 | 162 | 4 |
| 2025-09 | $604,194 | 92 | 62% | 4% | $4,356,329 | 98 | 163 | 2 |
| 2025-10 | $919,219 | 85 | 65% | 1% | $4,557,242 | 120 | 193 | 3 |
| 2025-11 | $828,409 | 92 | 62% | 0% | $4,647,816 | 92 | 209 | 1 |
| 2025-12 | $674,376 | 60 | 61% | 0% | $4,656,963 | 128 | 190 | 1 |
| 2026-01 | $738,302 | 93 | 76% | 2% | $4,552,385 | 226 | 234 | 4 |
| 2026-02 | $840,301 | 93 | 89% | 1% | $4,434,994 | 394 | 209 | 5 |
| 2026-03 | $877,918 | 89 | 76% | 1% | $4,225,062 | 356 | 180 | 3 |
| 2026-04 | $917,166 | 102 | 77% | 1% | $4,125,127 | 244 | 242 | 2 |
| 2026-05 | $652,891 | 69 | 80% | 0% | $3,971,505 | 241 | 218 | 2 |